As the demand for new medicines grows, so does the need for better information to manage and execute the R&D processes. There is huge pressure to make informed decisions, especially during the project's early stages when the risk is high and before downstream costs are added. Pfizer sp... As the demand for new medicines grows, so does the need for better information to manage and execute the R&D processes. There is huge pressure to make informed decisions, especially during the project's early stages when the risk is high and before downstream costs are added. Pfizer sp...Dec. 1, 2007 06:30 PM EST Reads: 6,086 |







Daniel Eng has over 17 years of diverse IT experience in managing projects, leading technical teams, and developing enterprise applications within Fortune 100 companies. Currently at Pfizer Global Research and Development, Dan is leading efforts in transitioning business processes and applications into a SOA environment by using emerging technologies and agile management practices. Prior to Pfizer, he was an independent consultant helping his Fortune 500 clients in developing intranet sites, portable applications and e-commerce solutions. Dan has also worked in many e-commerce start-ups and healthcare organizations. He holds a BSEE degree from Polytechnic University and an MBA degree from Gonzaga University.



















